Our findings suggest that it is safe to delay RRSO until age 45–50 for women with PVs in RAD51D and possibly later for women with PVs in BRIP1 or RAD51C. Overall, these data reiterate the importance of identifying PVs in these genes, given the elevated risk of ovarian cancer in the proband and the family. The gene discussed is RAD51D; the disease is ovarian carcinoma.